COMMUNIQUÉS West-GlobeNewswire

Exalenz to Present Positive Clinical Data for the Breath ID® 13C-Methacetin Breath Test System at the Liver Meeting® 2018
05/11/2018
MODI’IN, Israel and MANASQUAN, N.J., Nov. 05, 2018 (GLOBE NEWSWIRE) -- Exalenz Bioscience Ltd. (TASE: EXEN), a leader in developing and marketing non-invasive medical devices for diagnosing and monitoring a range of [...]
Novartis R&D update highlights industry leading development pipeline including potential blockbusters and advanced therapy platforms
05/11/2018
26 potential blockbusters in confirmatory development[1]. 13 projects in clinical development across Cell, Gene & Radioligand therapies. 60 major submissions[2] planned from 2019 to 2021 AVXS101 in SMA type 1 on [...]
ERYTECH to Host KOL Breakfast Symposium with Audio Webcast on November 7, 2018
05/11/2018
LYON, France and CAMBRIDGE, Mass., Nov. 05, 2018 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext Paris: ERYP - Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating drug [...]
ERYTECH tiendra un colloque avec des leaders d’opinion retransmis en direct le 7 novembre 2018
05/11/2018
LYON, France et CAMBRIDGE, Mass., 05 nov. 2018 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext Paris : ERYP - Nasdaq : ERYP), société biopharmaceutique de stade clinique développant des thérapies innovantes à partir de sa [...]
Semaglutide demonstrated superior improvements in glycaemic control vs placebo in adults with type 2 diabetes
05/11/2018
Read the full release Boston, US, 2 April 2016 - Findings from the first phase 3a clinical trial for semaglutide, an investigational glucagon-like peptide-1 (GLP-1) analogue, demonstrated that treatment with semaglutide [...]
Victoza® (liraglutide 1.8 mg) provided superior HbA1c reductions in adults with type 2 diabetes compared to continued sitagliptin treatment
05/11/2018
Read the full release Boston, US, 2 April 2016 - Findings from a clinical trial comparing Victoza ® (liraglutide 1.8 mg) and sitagliptin (100 mg), both in combination with metformin, demonstrated that switching from [...]
Saxenda® demonstrated significant improvements in cardiometabolic risk factors over three years compared with placebo
05/11/2018
Read the full release with references in PDF Boston, US, 4 April 2016 - Today, new data from the three-year part of the phase 3a SCALE(TM) ( S atiety and C linical A diposity - L iraglutide E vidence) Obesity and [...]
Semaglutide demonstrated superior glycaemic control vs insulin glargine U100 in adults with type 2 diabetes
05/11/2018
Read the full release with references Orlando, US, 27 May 2016 - Findings from a phase 3a clinical trial for semaglutide, an investigational glucagon-like peptide-1 (GLP-1) analogue, demonstrated that treatment with [...]
Three-year data show early response to Saxenda® resulted in improvements in weight loss and cardiometabolic risk factors
05/11/2018
Read the full release Gothenburg, Sweden, 2 June 2016 - Today, data from a post hoc analysis of the three-year part of the phase 3a SCALE(TM) (Satiety and Clinical Adiposity - Liraglutide Evidence) Obesity and [...]
Tresiba® (insulin degludec injection U-100) demonstrated significantly lower rates of overall, nocturnal and severe hypoglycaemia vs insulin glargine U-100
05/11/2018
New Orleans, US, 11 June 2016 - New findings from the two phase 3b SWITCH trials showed that treatment with long-acting basal insulin Tresiba ® (insulin degludec injection U-100) resulted in significantly lower rates of [...]
Semaglutide demonstrated superior improvements in glycaemic control vs sitagliptin (SUSTAIN 2) and exenatide ER (SUSTAIN 3) in two clinical trials in adults with type 2 diabetes
05/11/2018
New Orleans, US, 12 June 2016 - Findings from two phase 3a clinical trials for semaglutide, an investigational glucagon-like peptide-1 (GLP-1) analogue, were presented today at the American Diabetes Association 76 th [...]
Faster-acting insulin aspart showed a statistically significant reduction in HbA1c in type 1 diabetes and a comparable HbA1c reduction in type 2 diabetes versus NovoRapid® (insulin aspart)
05/11/2018
Faster-acting insulin aspart improved postprandial glucose (PPG) control in type 1 and type 2 diabetes New Orleans, US, 13 June 2016 - New phase 3a findings showed that faster-acting insulin aspart demonstrated a [...]
Victoza® significantly reduced the risk of major cardiovascular events and death in adults with type 2 diabetes in the LEADER trial
05/11/2018
New Orleans, US, 13 June 2016 - Novo Nordisk today announced that Victoza ® (liraglutide) significantly reduced the risk of the composite primary endpoint of cardiovascular (CV) death, non-fatal myocardial infarction ( [...]
Adults with type 2 diabetes treated with Xultophy® (IDegLira) were up to 4.5 times more likely to reach glycaemic targets without hypoglycaemia and weight gain vs up-titration with...
05/11/2018
Adults with type 2 diabetes treated with Xultophy® (IDegLira) were up to 4.5 times more likely to reach glycaemic targets without hypoglycaemia and weight gain vs up-titration with insulin glargine U100 Munich, Germany [...]
Semaglutide demonstrated superior HbA1c reduction vs placebo as add-on to basal insulin alone or with metformin in adults with type 2 diabetes
05/11/2018
Munich, Germany, 13 September 2016 - Novo Nordisk today announced that semaglutide, an investigational glucagon-like peptide-1 (GLP-1) analogue administered once-weekly, significantly improved glycaemic control compared [...]
Saxenda® provides consistent weight loss and improvements in blood glucose control across BMI categories after three years of treatment
05/11/2018
Munich, Germany, 14 September 2016 - Results from a post hoc analysis of the three-year part of the phase 3a SCALE (Satiety and Clinical Adiposity - Liraglutide Evidence) Obesity and Prediabetes trial show that people [...]
Victoza® lowered the progression of kidney damage in adults with type 2 diabetes at high CV risk
05/11/2018
Munich, Germany, 15 September 2016 - Novo Nordisk today announced that the progression of kidney damage was significantly lower with Victoza ® treatment vs placebo, as measured by urinary albumin creatinine ratio, both [...]
Semaglutide reduced major cardiovascular events by 26% in adults with type 2 diabetes at high cardiovascular risk
05/11/2018
Munich, Germany, 16 September 2016 - Novo Nordisk today announced that semaglutide, an investigational glucagon-like peptide-1 (GLP-1) analogue administered once-weekly, significantly reduced the risk of the primary [...]
Sandoz decides not to pursue US biosimilar rituximab; will focus on robust biosimilar portfolio for unmet access and sustainability needs
02/11/2018
Decision follows FDA request for additional information to complement submission for biosimilar rituximab Sandoz stands behind safety, efficacy and quality of our biosimilar rituximab, which is already approved in EU, [...]

Pages